Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer [Gastrointestinal Cancer]

Conclusion Olaparib/paclitaxel is active in the treatment of patients with metastatic gastric cancer, with a greater OS benefit in ATMlow patients. A phase III trial in this setting is under way.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Combined Modality, Translational Oncology Gastrointestinal Cancer Source Type: research